PolyPeptide Group AG and its consolidated subsidiaries (“PolyPeptide”) is a specialized Contract Development & Manufacturing Organization (CDMO) for peptide-based active pharmaceutical ingredients. By supporting its customers mainly in pharma and biotech, it contributes to the health of millions of patients across the world. PolyPeptide serves a fast-growing market, offering products and services from pre-clinical through to commercial stages. Its broad portfolio reflects the opportunities in drug therapies across areas and with a large exposure to metabolic diseases, including GLP-1. Dating back to 1952, PolyPeptide today runs a global network of six GMP-certified facilities in Europe, the U.S. and India. PolyPeptide’s shares (SIX: PPGN) are listed on SIX Swiss Exchange. Find out more about our current vacancies at: https://polypeptide.teamtailor.com/
Looking for a particular PolyPeptide Group employee's phone or email?
The PolyPeptide Group annual revenue was $300 million in 2026.
Stéphane Varray is the Chief Commercial Officer (CCO) of PolyPeptide Group.
1,034 people are employed at PolyPeptide Group.
PolyPeptide Group is based in Zug, Zug.
The NAICS codes for PolyPeptide Group are [54171, 54, 325414, 32541, 32, 541, 325, 5417, 541711, 3254].
The SIC codes for PolyPeptide Group are [28, 283].